In the early stages of prostate cancer, the most common symptom is frequent urination, especially at night.

Age, family history of prostate cancer, and African American race are all risk factors for prostate cancer.

The recommended age for men to start regular prostate cancer screenings is 50 years old.

Prostate-specific antigen (PSA) test, digital rectal exam (DRE), and biopsy are all commonly used to detect prostate cancer.

Surgery is the most common treatment for localized prostate cancer.

Hormonal therapy is often used for advanced prostate cancer to reduce the levels of testosterone, which can slow the growth of cancer cells.

Prostate-specific antigen (PSA) is a protein produced by prostate cancer cells that can be detected in the blood.

The Gleason score is used to determine the stage of cancer, assess the aggressiveness of cancer, and predict the response to treatment.

CT scan is commonly used to evaluate the spread of prostate cancer.

Radical prostatectomy is the term used to describe the surgical removal of the prostate gland.

External beam radiation therapy, brachytherapy, and intensity-modulated radiation therapy (IMRT) are all commonly used to treat prostate cancer.

Leuprolide is the name of the medication commonly used to reduce testosterone levels in prostate cancer treatment.

Docetaxel, cabazitaxel, and mitoxantrone are all commonly used to treat advanced prostate cancer.

Pembrolizumab, nivolumab, and ipilimumab are all immunotherapy drugs that have shown promise in treating prostate cancer.

Radium-223 is the targeted therapy drug used to treat prostate cancer that has spread to the bones.